

BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

CIN: L24233MP1985PLC002709

Registered Office: 11/12, Sector E Sanwer Road, Indore-452015 (M.P.)

Tel. 0731-2723016; Email id- bcplcompliance@gmail.com;

Website- www.biofilgroup.net; Fax: 0731-2723017

Date: 11th February, 2025

To, The Secretary (DCS/Compliance), Corporate Relationship Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai-400001	To, The Secretary (Listing/Compliance), National Stock Exchange of India Limited , Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Mumbai – 400051
--	--

Subject: Outcome of Board Meeting held on Tuesday 11th February, 2025 pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Reference: Biofil Chemicals and Pharmaceuticals Limited (BSE Scrip Code: 524396; NSE Symbol: BIOFILCHEM; ISIN: INE829A01014)

Dear Sir/Madam,

With reference to the above captioned subject and as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of the Company (Serial No. 06/2024-2025) held today i.e., Tuesday, 11th day of February, 2025, has inter alia, considered and approved the following businesses:

1. Un-audited Financial Results of the Company for the quarter as well as nine months ended on 31st December, 2024 along with the Limited Review Report thereon.
2. Proposal for Confirmation of appointment of Mr. Meet Shah, as a Director under the Category of Promoter Non-Executive Director of the Company for approval of members which is being obtained through Postal Ballot.
3. Cancellation of agreement entered on 13th August, 2024 between company and Cyano Pharma Private Limited for disposal of undertaking on situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore – 452015.
4. Proposal to sell, transfer or otherwise dispose of Leasehold land right & building situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore – 452015 Madhya Pradesh to Formo Plast Private Limited (Related Party), for approval of members which is being obtained through Postal Ballot.
5. Proposal to sell, transfer or otherwise dispose of plant & machineries, furniture, fixtures, scraps, structure, tools, manufacturing equipments and other assets apart from leasehold land and building situated at 11/12, Sector 'E', Sanwer Road Industrial Area, Indore – 452015 Madhya Pradesh to Cyano Pharma Private Limited (Related Party) for approval of members which is being obtained through Postal Ballot.
6. Review and approve the policy on Related Party Transactions w.e.f. 11th February, 2025.
7. Approval of Notice of postal ballot for passing proposed Resolutions with Explanatory statement thereto, e-voting, instruction & other particulars as required and the Board has authorized Managing Director of the Company to conduct postal ballot e voting process and sign and send the notice of Postal Ballot along with other documents and proceed for postal ballot e-voting process with due course of time.
8. Other routine business with the permission of Chair.

Further, copy of aforesaid Un-Audited Financial Results of the Company shall also be submitted in XBRL mode within 24 hours from the conclusion of Board Meeting.

The aforesaid Un-Audited Financial Results of the Company shall also be uploaded on the Company's website i.e. www.biofilgroup.net and on the website of the Stock Exchanges i.e., at www.bseindia.com and www.nseindia.com. Further, publication containing a Quick Response code and the details of the webpage where complete financial results of the Company are available will be published in Hindi and English Newspapers with in prescribed time limit.

Furthermore, Continuous Disclosure as required pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 with reference to the Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 is being filed separately.

The above information will also be available on the website of the Company at www.biofilgroup.net.

The Meeting of the Board of Directors commenced at 03.00 PM and concluded at 5.15 P.M.

This is for your information and record.

Thanking you.

Yours Faithfully,

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LIMITED

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
DIN: 00028819

Enclosure: Un-Audited Financial Results along with limited review report for the quarter as well as nine months ended on 31st December, 2024.

XVII	Total Comprehensive Income for the period (XIII + XIV) (Comprising Profit or Loss and other Comprehensive income for the period)	16.46	2.43	9.33	35.81	46.05	90.13
XVIII	Paid-Up equity share capital (face value of Rs 10/- each)	1627.38	1627.38	1627.38	1627.38	1627.38	1627.38
XIX	Reserves (Excluding Revaluation Reserve)						(183.30)
XX	Earnings per equity shares (for continuing operation):						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
XXI	Earnings Per Equity Share (for discontinued operation)						
	(1) Basic (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted (Rs)	0.00	0.00	0.00	0.00	0.00	0.00
XXII	Earnings Per Equity Share (for continuing & discontinued operation)						
	(1) Basic (Rs)	0.10	0.01	0.06	0.22	0.28	0.44
	(2) Diluted (Rs)	0.10	0.01	0.06	0.22	0.28	0.44

- The above unaudited financial results for the Quarter and nine month ended December 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 11, 2025. The above results have been reviewed by statutory Auditors of the company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, who have expressed an unmodified opinion. The Company's Management has exercised necessary due diligence to ensure that the financial results provide a true and fair view of its affairs.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- 3 The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments
a. Pharma Division
b. Chemicals Division.
- 4 The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary.
- 5 The aforesaid un-audited financial Results will be uploaded on the Company's website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.

Date: 11th February, 2025

Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)



Biofil Chemicals and Pharmaceuticals Limited

Registered Office: 11/12, Sector-'E' Sanwer Road, Industrial Area, Indore (M.P.)
CIN L24233MP1985PLC002709

Email Id:bcplcompliance@gmail.com Phone No. 0731-2426718,
Website: www.biofilgroup.net

Segment wise Revenue, Results and Capital Employed for quarter ended and nine month ended 31st December 2024

(Amount in Lakhs)

S.No.	Particulars	QUARTER ENDED			NINE MONTH ENDED		Year Ended
		3 months ended on 31/12/2024	Previous 3 months ended on 30/09/2024	Corresponding 3 months ended in previous year on 31/12/2023	Year to date figures for Current period ended 31/12/2024	Year to date figures for Previous period ended 31/12/2023	Previous Year ended on 31/03/2024
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue						
	Pharma Unit	1,204.77	182.20	179.12	2,126.60	1,271.71	2,786.79
	Chemicals Division	214.75	59.06	324.03	378.52	1,211.55	1,216.74
	Gross Turnover	1,419.52	241.26	503.15	2,505.12	2,483.26	4,003.53
2	Segment Results						
	Pharma Unit	-2.34	-7.02	-4.14	-7.40	-22.07	1.07
	Chemicals Division	25.41	11.20	15.41	58.30	82.87	88.56
	Total Segment Profit Before Tax	23.07	4.18	11.27	50.90	60.80	89.63
	Interest Income	0.06	0.00	0.07	0.11	0.13	0.85
	Interest Expenses	0.97	0.90	0.00	2.78	1.88	3.95
	Other Unallocable Income net of Expenditure						
	Profit Before Tax	22.16	3.28	11.33	48.23	59.05	86.53
3	Capital Employed						
	Segment Assets (A)						
	Pharma Division	3,040.03	1,994.49	1,993.01	3,040.03	1,993.01	2,347.94
	Chemicals Division	1,478.95	2,111.29	2,251.55	1,478.95	2,251.55	2,360.33
	Total (A)	4,518.98	4,105.77	4,244.56	4,518.98	4,244.56	4,708.27
	Segment Liabilities (B)						
	Pharma Division	2,483.46	1,422.05	1,658.78	2,483.46	1,658.78	1,976.69
	Chemicals Division	179.41	868.56	806.80	179.41	806.80	911.30
	Total (B)	2,662.88	2,290.60	2,465.58	2,662.88	2,465.58	2,887.99
	Total Capital Employed (Segment Assets-Segment Liabilities)						
	Pharma Division	556.57	572.44	334.23	556.57	334.23	371.25
	Chemicals Division	1,299.54	1,242.73	1,444.75	1,299.54	1,444.75	1,449.03
	Total Capital Employed (Segment Assets-Segment Liabilities)	1,856.10	1,815.17	1,778.98	1,856.10	1,778.98	1,820.28

Date: 11th February, 2025
Place : Indore

FOR BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.

RAMESH SHAH
CHAIRMAN & MANAGING DIRECTOR
(DIN: 00028819)

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Biofil Chemicals and Pharmaceuticals Limited
Indore (M.P.)

We have reviewed the accompanying statement of unaudited Standalone Financial results ("the statement") of **Biofil Chemicals and Pharmaceuticals Limited** ("the company") for the quarter ended 31st December, 2024 and year to date from 01st April, 2024 to 31st December, 2024 attached herewith. The Statement has been prepared by the Company's Management pursuant to requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 as amended ("the listing regulations").

This statement, which is the responsibility of the Company's management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with rule 3 of Companies (Indian Accounting Standards) Rules, 2015 (as amended), in compliance with Regulation 33 issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures, A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would be



aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **MAHESHWARI & GUPTA**
Chartered Accountants
FRN: 006179C



CA. SUNIL MAHESHWARI
Partner
M. No. 403346

Place: Indore

Date: 11/02/2025

UDIN: 25403346BMIIED1075